Who is the richest pharmaceutical CEO?

David Ricks Tops Pharma CEO Pay in 2025

For the second year running, David Ricks, CEO of Eli Lilly, has claimed the title of highest-paid executive in the pharmaceutical industry. As of 2025, his total compensation far exceeded the average CEO pay across the 12 largest drug companies, which stood at $27 million. While exact figures for Ricks’ package weren’t disclosed in full, sources indicate it was significantly above that benchmark, driven by performance-based incentives tied to the company’s breakthroughs in diabetes and weight-loss medications.

Lilly’s surge in revenue—fueled by the success of drugs like Mounjaro and Zepbound—has translated into strong returns for shareholders and record profits. This financial momentum has clearly reflected in executive compensation, with Ricks at the helm during one of the most transformative periods in the company’s history.

Still, such figures invite scrutiny. With prescription drug costs under constant public and political pressure, the widening gap between CEO earnings and average worker pay continues to spark debate. The $27 million average for top pharma CEOs—already a slight increase from previous years—highlights the immense value placed on leadership in an industry where innovation can mean billions in returns.

That said, compensation reporting varies widely across global firms, influenced by regional regulations, corporate governance standards, and accounting practices. Some companies bundle stock awards and bonuses differently, making direct comparisons tricky. Still, by most metrics, Ricks’ position at the top is clear.

As the pharmaceutical landscape evolves—with increasing focus on biotech advances and global access to medicine—the role of the CEO becomes ever more pivotal. And in 2025, no one in the sector commanded a higher paycheck than David Ricks. His leadership at Lilly has not only reshaped the company’s trajectory but also redefined what success looks like at the top of big pharma.